Can genomic signatures predict response to systemic therapy?

M. Tsao (Toronto, Canada)

Source: Annual Congress 2013 –Biological signatures in thoracic oncology
Session: Biological signatures in thoracic oncology
Session type: Symposium
Number: 1951

Slide presentationMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Tsao (Toronto, Canada). Can genomic signatures predict response to systemic therapy?. Annual Congress 2013 –Biological signatures in thoracic oncology

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
A change in blood transcriptional signatures accompanies successful tuberculosis therapy
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools
Year: 2012

TB following targeted and biological therapy: can we predict it?
Source: Virtual Congress 2020 – Tuberculosis and comorbidities
Year: 2020

Can intermediate monocytes predict response to infliximab therapy in sarcoidosis?
Source: Eur Respir J 2016; 48: 1242-1245
Year: 2016

How to better assess and predict disease progression and treatment response: home-based spirometry, biomarkers or …?
Source: International Congress 2019 – High-tech in interstitial lung diseases: just hype and gadgets?
Year: 2019

A sputum gene expression signature predicts oral corticosteroid response in asthma
Source: Eur Respir J, 49 (6) 1700180; 10.1183/13993003.00180-2017
Year: 2017

Immunoproteasome function as a potential biomarker for asthma severity and response to therapy
Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease
Year: 2021

Prediction of long-term effect of anti-angiogenic therapy in lung cancer patients by monitoring early changes in circulating-tumor DNA (ctDNA).
Source: Virtual Congress 2020 – Biological aspects of lung cancer
Year: 2020

The influence of TNFα gene polymorphism on the therapeutic response in patients with sarcoidosis
Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis
Year: 2012

The microbiome, cancer development and response to therapy
Source: International Congress 2018 – Scientific Year in Review
Year: 2018

Does lung function predict response to therapy in PAH associated with connective tissue disease?
Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology
Year: 2012

Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma?
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020

The way to improve the steroid sensitivity of target cells of patients with severe therapy resistant asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 313s
Year: 2006

Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021
Year: 2022

Does a predominant clinical COPD phenotype predict different outcome responses to pulmonary rehabilitation?
Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care
Year: 2012

30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?
Source: ERJ Open Res, 4 (4) 00030-2018; 10.1183/23120541.00030-2018
Year: 2018

The future of targeted therapies for sarcoidosis
Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis
Year: 2005

Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score.
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021

Does combination therapy lead to better adherence in asthma?
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

COPD phenotypes and co-morbidities: to what extent do they affect a successful response to rehabilitation?
Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD
Year: 2011